Ascofuranone suppresses EGF-induced HIF-1α protein synthesis by inhibition of the Akt/mTOR/p70S6K pathway in MDA-MB-231 breast cancer cells

Toxicology and Applied Pharmacology

Volumn 273, Issue 3, 2013, Pages 542-550

  Jeong, Yun Jeong ^a   Cho, Hyun Ji ^a   Magae, Junji ^b   Lee, In Kyu ^c   Park, Keun Gyu ^c   Chang, Young Chae ^a  

^a Catholic University of Daegu   (South Korea)

^b Magae Bioscience Institute   (Japan)

^c Kyungpook National University School of Medicine   (South Korea)

Author keywords

Angiogenesis; Ascofuranone; HIF 1 ; VEGF

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; ANGIOGENESIS INHIBITOR; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ANTIBIOTIC AGENT; ASCOFURANONE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; ISOPRENOID; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; P70S6K KINASE; PROTEIN KINASE; PROTEIN KINASE B; RAPAMYCIN; SB 203589; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; VASCULOTROPIN; WORTMANNIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; GENE CONTROL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

ANGIOGENESIS; ASCOFURANONE; HIF-1Α; VEGF;

ANGIOGENESIS INHIBITORS; ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; CHROMATIN IMMUNOPRECIPITATION; EPIDERMAL GROWTH FACTOR; FEMALE; GENE EXPRESSION REGULATION; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MCF-7 CELLS; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SESQUITERPENES; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TRANSCRIPTIONAL ACTIVATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

ASCOCHYTA;

EID: 84888867015     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2013.09.027     Document Type: Article

References (42)

1. Bruick R.K., McKnight S.L. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 2001, 294:1337-1340.
2. Buchholz T.A., Tu X., Ang K.K., Esteva F.J., Kuerer H.M., Pusztai L., Cristofanilli M., Singletary S.E., Hortobagyi G.N., Sahin A.A. Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin-based neoadjuvant chemotherapy. Cancer 2005, 104:676-681.
3. Chang Y.C., Cho H.J. Ascofuranone stimulates expression of adiponectin and peroxisome proliferator activated receptor through the modulation of mitogen activated protein kinase family members in 3T3-L1, murine pre-adipocyte cell line. Biochem. Biophys. Res. Commun. 2012, 422:423-428.
4. Cho H.J., Kang J.H., Kwak J.Y., Lee T.S., Lee I.S., Park N.G., Nakajima H., Magae J., Chang Y.C. Ascofuranone suppresses PMA-mediated matrix metalloproteinase-9 gene activation through the Ras/Raf/MEK/ERK- and Ap1-dependent mechanisms. Carcinogenesis 2007, 28:1104-1110.
5. Cho H.J., Kang J.H., Kim T., Park K.K., Kim C.H., Lee I.S., Min K.S., Magae J., Nakajima H., Bae Y.S., Chang Y.C. Suppression of PAI-1 expression through inhibition of the EGFR-mediated signaling cascade in rat kidney fibroblast by ascofuranone. J. Cell. Biochem. 2009, 107:335-344.
6. Dales J.P., Garcia S., Meunier-Carpentier S., Andrac-Meyer L., Haddad O., Lavaut M.N., Allasia C., Bonnier P., Charpin C. Overexpression of hypoxia-inducible factor HIF-1alpha predicts early relapse in breast cancer: retrospective study in a series of 745 patients. Int. J. Cancer 2005, 116:734-739.
7. Downward J., Parker P., Waterfield M.D. Autophosphorylation sites on the epidermal growth factor receptor. Nature 1984, 311:483-485.
8. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat. Med. 2003, 9:669-676.
9. Fukuda R., Hirota K., Fan F., Jung Y.D., Ellis L.M., Semenza G.L. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J. Biol. Chem. 2002, 277:38205-38211.
10. Gingras A.C., Gygi S.P., Raught B., Polakiewicz R.D., Abraham R.T., Hoekstra M.F., Aebersold R., Sonenberg N. Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. Genes Dev. 1999, 13:1422-1437.
11. Han Z.B., Ren H., Zhao H., Chi Y., Chen K., Zhou B., Liu Y.J., Zhang L., Xu B., Liu B., Yang R., Han Z.C. Hypoxia-inducible factor (HIF)-1 alpha directly enhances the transcriptional activity of stem cell factor (SCF) in response to hypoxia and epidermal growth factor (EGF). Carcinogenesis 2008, 29:1853-1861.
12. Hay N., Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 2004, 18:1926-1945.
13. Hiraga T., Kizaka-Kondoh S., Hirota K., Hiraoka M., Yoneda T. Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer. Cancer Res. 2007, 67:4157-4163.
14. Hosokawa T., Okutomi T., Sawada M., Ando K., Tamura G. Unusual concentration of urine and prevention of polydipsia by fungal prenylphenols in DOCA hypertensive rats. Eur. J. Pharmacol. 1981, 69:429-438.
15. Hui E.P., Chan A.T., Pezzella F., Turley H., To K.F., Poon T.C., Zee B., Mo F., Teo P.M., Huang D.P., Gatter K.C., Johnson P.J., Harris A.L. Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clin. Cancer Res. 2002, 8:2595-2604.
16. Hwang S.L., Chang H.W., Lee I.K., Yang B.K., Magae J., Chang Y.C. Ascofuranone prevents ER stress-induced insulin resistance via activation of AMP-activated protein kinase in L6 myotube cells. Biochem. Biophys. Res. Commun. 2010, 396:967-972.
17. Jefferies H.B., Fumagalli S., Dennis P.B., Reinhard C., Pearson R.B., Thomas G. Rapamycin suppresses 5'TOP mRNA translation through inhibition of p70s6k. EMBO J. 1997, 16:3693-3704.
18. Jeong J.H., Kang S.S., Park K.K., Chang H.W., Magae J., Chang Y.C. p53-independent induction of G1 arrest and p21WAF1/CIP1 expression by ascofuranone, an isoprenoid antibiotic, through downregulation of c-Myc. Mol. Cancer Ther. 2010, 9:2102-2113.
19. Jeong J.H., Jeong Y.J., Cho H.J., Shin J.M., Kang J.H., Park K.K., Park Y.Y., Chung I.K., Chang H.W., Magae J. Ascochlorin inhibits growth factor-induced HIF-1alpha activation and tumor-angiogenesis through the suppression of EGFR/ERK/p70S6K signaling pathway in human cervical carcinoma cells. J. Cell. Biochem. 2012, 113:1302-1313.
20. Ke Q., Costa M. Hypoxia-inducible factor-1 (HIF-1). Mol. Pharmacol. 2006, 70:1469-1480.
21. Kondo Y., Arii S., Mori A., Furutani M., Chiba T., Imamura M. Enhancement of angiogenesis, tumor growth, and metastasis by transfection of vascular endothelial growth factor into LoVo human colon cancer cell line. Clin. Cancer Res. 2000, 6:622-630.
22. Lee J.E., Chung K.W., Han W., Kim S.W., Shin H.J., Bae J.Y., Noh D.Y. Effect of estrogen, tamoxifen and epidermal growth factor on the transcriptional regulation of vascular endothelial growth factor in breast cancer cells. Anticancer Res. 2004, 24:3961-3964.
23. Liu C., Shi Y., Du Y., Ning X., Liu N., Huang D., Liang J., Xue Y., Fan D. Dual-specificity phosphatase DUSP1 protects overactivation of hypoxia-inducible factor 1 through inactivating ERK MAPK. Exp. Cell Res. 2005, 309:410-418.
24. Magae J., Suzuki S., Nagai K., Yamasaki M., Ando K., Tamura G. In vitro effects of an antitumor antibiotic, ascofuranone, on the murine immune system. Cancer Res. 1986, 46:1073-1078.
25. Maxwell P.H., Wiesener M.S., Chang G.W., Clifford S.C., Vaux E.C., Cockman M.E., Wykoff C.C., Pugh C.W., Maher E.R., Ratcliffe P.J. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999, 399:271-275.
26. Passaniti A., Taylor R.M., Pili R., Guo Y., Long P.V., Haney J.A., Pauly R.R., Grant D.S., Martin G.R. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab. Invest. 1992, 67:519-528.
27. Peng X.H., Karna P., Cao Z., Jiang B.H., Zhou M., Yang L. Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1alpha signal pathways increases resistance to apoptosis by up-regulating survivin gene expression. J. Biol. Chem. 2006, 281:25903-25914.
28. Price J.T., Tiganis T., Agarwal A., Djakiew D., Thompson E.W. Epidermal growth factor promotes MDA-MB-231 breast cancer cell migration through a phosphatidylinositol 3'-kinase and phospholipase C-dependent mechanism. Cancer Res. 1999, 59:5475-5478.
29. Rae J.M., Scheys J.O., Clark K.M., Chadwick R.B., Kiefer M.C., Lippman M.E. EGFR and EGFRvIII expression in primary breast cancer and cell lines. Breast Cancer Res. Treat. 2004, 87:87-95.
30. Rojas M., Yao S., Lin Y.Z. Controlling epidermal growth factor (EGF)-stimulated Ras activation in intact cells by a cell-permeable peptide mimicking phosphorylated EGF receptor. J. Biol. Chem. 1996, 271:27456-27461.
31. Sasaki H., Hosokawa T., Sawada M., Ando K. Isolation and structure of ascofuranone and ascofranol, antibiotics with hypolipidemic activity. J. Antibiot. (Tokyo) 1973, 26:676-680.
32. Sawada M., Hosokawa T., Okutomi T., Ando K. Hypolipidemic property of ascofuranone. The Journal of antibiotics 1973, 26:681-686.
33. Schalm S.S., Fingar D.C., Sabatini D.M., Blenis J. TOS motif-mediated raptor binding regulates 4E-BP1 multisite phosphorylation and function. Curr. Biol. 2003, 13:797-806.
34. Semenza G. Signal transduction to hypoxia-inducible factor 1. Biochem. Pharmacol. 2002, 64:993-998.
35. Semenza G.L. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol. Med. 2002, 8:S62-S67.
36. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 2003, 3:721-732.
37. Shiba T., Kido Y., Sakamoto K., Inaoka D.K., Tsuge C., Tatsumi R., Takahashi G., Balogun E.O., Nara T., Aoki T., Honma T., Tanaka A., Inoue M., Matsuoka S., Saimoto H., Moore A.L., Harada S., Kita K. Structure of the trypanosome cyanide-insensitive alternative oxidase. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:4580-4585.
38. Stoica G.E., Franke T.F., Wellstein A., Czubayko F., List H.J., Reiter R., Morgan E., Martin M.B., Stoica A. Estradiol rapidly activates Akt via the ErbB2 signaling pathway. Mol. Endocrinol. 2003, 17:818-830.
39. Takatsuki A., Nakatani N., Morimoto M., Tamura G., Matsui M., Arima K., Yamaguchi I., Misato T. Antiviral and antitumor antibiotics. XX. Effects of rotenone, deguelin, and related compounds on animal and plant viruses. Appl. Microbiol. 1969, 18:660-667.
40. Wang G.L., Jiang B.H., Rue E.A., Semenza G.L. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:5510-5514.
41. Zheng X., Jiang F., Katakowski M., Zhang Z.G., Lu Q.E., Chopp M. ADAM17 promotes breast cancer cell malignant phenotype through EGFR-PI3K-AKT activation. Cancer Biol. Ther. 2009, 8:1045-1054.
42. Zhong H., Chiles K., Feldser D., Laughner E., Hanrahan C., Georgescu M.M., Simons J.W., Semenza G.L. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res. 2000, 60:1541-1545.